Clinical trial
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When…
NCT00044057 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00044057 |
|---|---|
| Title | A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator) |
| Official title | A Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients With Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Ischemic Stroke |
| Intervention type | Drug |
| Interventions | YM872 (zonampanel), t-PA (alteplase) |
| Start date | Dec 1, 2000 |
| Completion | Jan 1, 2003 |
| First posted | Aug 20, 2002 |
| Last update posted | Apr 3, 2006 |
| Countries | Austria, Belgium, Canada, Germany, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: